FLT3 and acute myeloid leukemia: In addition, in immune-depleted mice engrafted with AML cell line or PD AML cells with MLL1-r with FLT3 mutation, compared to treatment with each agent alone co-treatment with SNDX-5613 (the clinical grade version of SNDX-50469) and pan-BET inhibitor OTX015 or p300/CBP inhibitor GNE-781 significantly reduced AML burden and improved overall survival of the mice [24, 27].